Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Clinical Trials

Livagen

Lys-Glu-Asp-Ala, Tetrapeptide KEDA

Quick Stats
Studies 10
Trials 22
Overview Studies Clinical Trials
Completed NA INTERVENTIONAL NCT02700958

Remote Ischemic Preconditioning as a Method Against Subclinical Renal Injury and Contrast-induced Nephropathy

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Contrast-induced nephropathy (CIN) has remained significant and severe complication of angiographic procedures despite the increasing use of preventative methods. It has been associated with prolonged hospital stay, high morality and the need for dialysis. Since classically used creatinine for diagnosing of CIN does not reflect the degree of tubular injury before 24-48 hours after exposure to contrast media alternative earlier biomarkers and preventative methods are needed. Remote ischemic preconditioning is a non-invasive and safe method which in some studies has been reported to protect against contrast-induced nephropathy. The purpose of this study is to evaluate the effect of remote ischemic preconditioning (RIPC) (1) as an additional method to standard treatment to prevent subclinical and clinical contrast-induced acute kidney injury and (2) to assess its effect on functional properties of arterial wall, organ damage biomarkers and low molecular weight metabolites.

Interventions

Name: Remote ischemic preconditioning
Type: PROCEDURE
Description: Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
Name: SHAM Remote ischemic preconditioning
Type: PROCEDURE
Description: SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes

Primary Outcomes

Measure: Change in carotid-femoral pulse wave velocity compared with baseline and SHAM subgroup
TimeFrame: 24 hours
Description: Carotid-femoral pulse wave velocity baseline measurement is performed. Second measuring is performed 24 hours after angiographic procedure. Change from baseline will be compared between RIPC and SHAM subgroups. Measuring is performed with SphygmoCor XCEL PWA and PWV Device.
Measure: Change in augmentation indices (augmentation index and heart rate-corrected augmentation index (AIx@75)) compared with baseline and SHAM subgroup
TimeFrame: 24 hours
Description: Augmentation indices baseline measurement is performed. Second measuring is performed 24 hours after angiographic procedure. Change from baseline will be compared between RIPC and SHAM subgroups. Measuring is performed with SphygmoCor XCEL PWA and PWV Device.

Trial Information

NCT ID

NCT02700958

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Tartu University Hospital

Last Updated

December 15, 2025

Related Peptides

KPV Thymogen Ovagen Cortagen Livagen Bronchogen Pancragen